<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04434872</url>
  </required_header>
  <id_info>
    <org_study_id>0680-14-TLV</org_study_id>
    <nct_id>NCT04434872</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation as a Treatment for Ulcerative Colitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <brief_summary>
    <textblock>
      Ulcerative colitis (UC) is characterized by a disrupted homeostasis of the commensal&#xD;
      bacterial population (dysbiosis). A promising therapy for restoration of the altered balance&#xD;
      of the enteric microbiota is fecal microbial transplantation (FMT).&#xD;
&#xD;
      FMT will ameliorate colitis via alterations of patients' microbiota and their&#xD;
      proteolytic-dependent effect on epithelial permeability.&#xD;
&#xD;
      Design: 80 patients will undergo 1:1 randomization for multiple FMT (Fecal Microbiota&#xD;
      Transplantation) from a healthy donor or autologous (placebo) through colonoscopy and rectal&#xD;
      enemas. The treating physicians and the patients will be blinded for the treatment arm.&#xD;
&#xD;
      At the FMT visit (first week), blood and stool samples will be taken and patients will be&#xD;
      filling out questionnaires to assess disease activity level.&#xD;
&#xD;
      Every 2 weeks patients will come to a clinic for a follow up visit. 8 weeks after FMT,&#xD;
      patients will undergo sigmoidoscopy to assess disease severity, biopsies will be taken as&#xD;
      well.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of budget&#xD;
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>8 weeks after FMT</time_frame>
    <description>A composite measure- Will be measured by SCCAI (Simple Clinical Colitis Activity Index) and by MAYO SCORE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histological remission assessed by sigmoidoscopy</measure>
    <time_frame>8 weeks after FMT</time_frame>
    <description>Will be assessed by sigmoidoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term remission assessed through questionnaires</measure>
    <time_frame>one year after FMT</time_frame>
    <description>Will be assessed through questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>FMT from a healthy donor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo FMT 4 times during the study:&#xD;
first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:&#xD;
A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.&#xD;
Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FMT from a self donated stool sample</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will undergo FMT 4 times during the study:&#xD;
first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:&#xD;
A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.&#xD;
Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colonoscopy</intervention_name>
    <description>Fecal microbiota transplantation through colonoscopy</description>
    <arm_group_label>FMT from a healthy donor</arm_group_label>
    <arm_group_label>FMT from a self donated stool sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastroscopy</intervention_name>
    <description>Fecal microbiota transplantation through gastroscopy</description>
    <arm_group_label>FMT from a healthy donor</arm_group_label>
    <arm_group_label>FMT from a self donated stool sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fecal Microbiota</intervention_name>
    <arm_group_label>FMT from a healthy donor</arm_group_label>
    <arm_group_label>FMT from a self donated stool sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Enema</intervention_name>
    <description>Fecal microbiota transplantation through enema</description>
    <arm_group_label>FMT from a healthy donor</arm_group_label>
    <arm_group_label>FMT from a self donated stool sample</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 3 month diagnosis of ulcerative colitis&#xD;
&#xD;
          -  Active Colitis disease with endoscopic score &gt;0&#xD;
&#xD;
          -  Ability to sign an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute neutrophilia (under 500 neutrophils)&#xD;
&#xD;
          -  Clostridium difficile infection&#xD;
&#xD;
          -  Exposure to antibiotics 2 weeks prior to enrollment.&#xD;
&#xD;
          -  Severe immune deficiency&#xD;
&#xD;
          -  Hospitalization&#xD;
&#xD;
          -  Proctitis involving less than 10cm of the rectum&#xD;
&#xD;
          -  Malignancy with the past 5 years (excluding BCC)&#xD;
&#xD;
          -  An unstable dose of steroids or 5ASA (5- aminosalicylic acid) with the past 2 weeks or&#xD;
             of immunomodulators or biologic therapy within the past 12 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Gastroentherology</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>June 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>June 14, 2020</last_update_submitted>
  <last_update_submitted_qc>June 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiota</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

